CNS (MS, Insomnia, Sleepiness, Emesis, Parkinson), Hyperglycemias,
Hot Flushes, Obesity
|
Categories |
Drug delivery, Novel Carrier |
|
Development Stage |
Concept has been proved in animal models (including sheep) for many diseases and various drugs including large molecules and peptides. Industrial upscale results. |
|
Patent Status |
Patents filed in United States, Europe, Japan, Israel, India and China; published in the United States, Europe and Japan |
|
Market |
With advances in biotechnology, nasal drug delivery is increasingly becoming a more viable alternative to oral and injectable routes of administration for an increasing number of drugs including peptides.. |
Highlights
-
Technology for efficient drug therapy by nasal delivery
-
Wide number of experiments in animal models
-
Examples: very efficient treatment and disease prevention in EAE mice (drugs: steroids, glatiramer acetate, new drug combinations), antiemetic in rat model (drug: granisetron), antiwrithing effect (drug: diazepam), malaria prevention and treatment ( drug: DHA), insomnia (drugs: benzodiazepine, melatonin, antihistamines ), obesity (drug: insulin, others) Parkinson rotational model (drug: apomorphine),
Our Innovation
-
Platform drug delivery carrier technology for approved or new drugs, single drugs or combination of drugs (also including new drug combinations).
Key Features
-
Improved delivery into the brain
-
Better bioavailability by nasal route than by oral or subcutaneous routes
-
Particularly important in crisis management such as for multiple sclerosis, Alzheimer, insomnia, glioma, sleepiness (EDS), epileptic seizures, hyperglycemia, hypoglycaemia, hot flushes, emesis, Parkinson rigidity
-
Carrier ingredients already have FDA approval for nasal delivery
-
Increase patient compliance - needle-free alternative for delivering drugs for acute and chronic conditions, allowing self-medication
Development Milestones
-
Proof of concept achieved in animal models
-
Planned Phase I and Phase II trials
The Opportunity
-
Seeking investment and cooperation for ongoing development of a number of drugs
-
Prior FDA ingredient approvals will lead to faster product approval process
1586128900.png)